...
机译:P3.02B-026 EGFR外显子19删除和EGFR-TKI治疗持续时间,具有EGFR-突变体肺癌患者T790M突变的频率
Department of Internal Medicine Division of Respirology Neurology and Rheumatology Kurume;
Kurume University School of Medicine;
Department of Genome Biology Kinki University Faculty of Medicine;
Kurume University School of Medicine;
Department of Internal Medicine Division of Respirology Neurology and Rheumatology Kurume;
Department of Internal Medicine Division of Respirology Neurology and Rheumatology Kurume;
Department of Internal Medicine Division of Respirology Neurology and Rheumatology Kurume;
Department of Internal Medicine Division of Respirology Neurology and Rheumatology Kurume;
Department of Genome Biology Kinki University Faculty of Medicine;
Department of Internal Medicine Division of Respirology Neurology and Rheumatology Kurume;
机译:P3.02B-026 EGFR外显子19删除和EGFR-TKI治疗持续时间,具有EGFR-突变体肺癌患者T790M突变的频率
机译:EGFR-突变体肺癌患者T790M突变频率的EGFR外显子19缺失和EGFR-TKI治疗持续时间
机译:初始表皮生长因子受体酪氨酸激酶抑制剂治疗和EGFR外显子抑制作用的抗T790M突变抗性抗性抗性抗肺癌患者的抗性抗性,抗血疱剂血管生长因子受体酪氨酸激酶激酶抑制剂
机译:接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
机译:EGFR-TKIs在非小细胞肺癌治疗中的有效性:一项荟萃分析。
机译:EGFR突变型肺癌患者中EGFR外显子19缺失和EGFR-TKI治疗持续时间与T790M突变频率的关系
机译:>初始表皮生长因子受体酪氨酸激酶抑制剂治疗和EGFR外显子抑制剂的抗血液抗性抗血液肺癌患者T790M突变抗性抗性后,抗抗血疱剂患者的抗性,抗抗血管生长因子受体酪氨酸激酶抑制剂 p>